Acute Cholecystitis in a Patient on Apixaban: Timing Surgery Against Bleeding Risk
A 71-year-old man with atrial fibrillation, hypertension and type 2 diabetes presents with 36 hours of right upper quadrant pain, fever of 38.6 C and nausea. He takes apixaban 5 mg twice daily and his last dose was 14 hours ago. Heart rate 104/min, blood pressure 138/82 mmHg, respiratory rate 20/min, oxygen saturation 96% on room air. The abdomen shows right upper quadrant tenderness with a positive Murphy sign and no peritonism. White cell count 15.2 x 10^9/L, total bilirubin 1.8 mg/dL, alkaline phosphatase 214 U/L, ALT 96 U/L, AST 88 U/L, lipase normal, creatinine 1.1 mg/dL (estimated creatinine clearance about 62 mL/min), INR 1.1. Ultrasound shows a distended gallbladder, 5 mm wall thickening, pericholecystic fluid, multiple stones, a sonographic Murphy sign, and a common bile duct of 4 mm with no visible stones. He is haemodynamically stable and improving on fluids. The next laparoscopic list with a free slot is in 48 hours and he asks whether the operation can wait.
1. Should the cholecystectomy go ahead in 48 hours? Justify your answer using the bleeding risk, the sepsis risk, and what would make you change the plan.
Read the worked answer
Yes, because this is grade II acute cholecystitis and early laparoscopic cholecystectomy, ideally within 72 hours of presentation, shortens hospital stay and reduces conversion and recurrence compared with delayed interval surgery. On the anticoagulant side, apixaban can be held for 48 hours before a procedure with moderate bleeding risk when creatinine clearance is above 50 mL/min; if he misses tonight's dose and operates in 48 hours, roughly 60 hours will have elapsed since the last tablet, which gives acceptable residual anticoagulant effect for a straightforward laparoscopic dissection. His stroke risk is only moderate (CHA2DS2-VASc 3 for age, hypertension and diabetes), so a brief interruption is safe and the risk of leaving a septic gallbladder exceeds the bleeding risk. Change the plan if he develops septic shock, generalised peritonitis, gallbladder perforation or emphysematous changes: operate emergently, accept the bleeding risk, and consider andexanet alfa (or prothrombin complex concentrate if unavailable). If operative risk became prohibitive, percutaneous cholecystostomy under local anaesthetic is the alternative that avoids reversal.
2. Write the perioperative anticoagulation plan, including bridging, restart timing, and the conversation you would have about stroke risk.
Read the worked answer
Stop apixaban now; the last dose will then be roughly 60 hours before incision. Do not bridge with low molecular weight heparin: in patients with non-valvular atrial fibrillation, bridging during direct oral anticoagulant interruption increases major and minor bleeding without reducing stroke, and it is not indicated for a two-day interruption in someone with a CHA2DS2-VASc score of 3. Confirm renal function on the morning of surgery because a falling creatinine clearance prolongs apixaban effect. Restart apixaban 24 hours after an uncomplicated laparoscopic cholecystectomy once haemostasis is secure, since this is a low-to-moderate bleeding risk procedure; wait 48-72 hours if there is a bile leak, bleeding or conversion to open surgery. Explain to the patient that his annual stroke risk of roughly 3% is not meaningfully increased by a two-day pause, whereas continuing the drug through surgery carries a real risk of intraoperative haemorrhage and conversion to open operation.
3. What antibiotic regimen and duration would you use, and does the bilirubin of 1.8 mg/dL with a 4 mm duct require further biliary imaging?
Read the worked answer
Start empirical cover for Enterobacterales and anaerobes, for example ceftriaxone 2 g daily plus metronidazole 500 mg three times daily, or amoxicillin-clavulanate if the illness is mild; use piperacillin-tazobactam if there is haemodynamic compromise or previous resistant organisms. Obtain blood cultures only if systemically unwell or if antibiotics have already been given. After successful source control, antibiotics can usually stop within 24 hours for mild disease and within 4-7 days for moderate disease; prolonged courses are not needed once the gallbladder is out. The bilirubin of 1.8 mg/dL with a 4 mm duct most likely reflects a stone that has already passed, causing the transient transaminase rise; a non-dilated duct on ultrasound makes retained choledocholithiasis unlikely. Do not order MRCP reflexively. Repeat liver tests in 24-48 hours; if bilirubin or alkaline phosphatase climbs, or the duct dilates, proceed to MRCP or intraoperative cholangiogram rather than assuming resolution.